| Pharmaceutical Information |
| Drug Name |
Norfloxacin |
| Drug ID |
BADD_D01587 |
| Description |
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. |
| Indications and Usage |
For the treatment of urinary tract infection |
| Marketing Status |
approved |
| ATC Code |
J01MA06; S01AE02 |
| DrugBank ID |
DB01059
|
| KEGG ID |
D00210
|
| MeSH ID |
D009643
|
| PubChem ID |
4539
|
| TTD Drug ID |
D0Q2PE
|
| NDC Product Code |
53104-7517 |
| UNII |
N0F8P22L1P
|
| Synonyms |
Norfloxacin | MK-0366 | MK 0366 | MK-366 | MK 366 | MK0366 | MK366 | Noroxin | AM-0715 | AM 0715 | AM0715 | AM-715 | AM 715 |
|
| Chemical Information |
| Molecular Formula |
C16H18FN3O3 |
| CAS Registry Number |
70458-96-7 |
| SMILES |
CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
